Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia

Completed · Phase 3

Conditions studied: Acute Myeloid Leukemia

In brief

Multicenter, randomized, open-label, parallel-group study of guadecitabine vs treatment choice (TC). Participants will be randomly assigned in a 1:1 ratio to either guadecitabine or TC. TC options include the 8 high or low intensity, locally available regimens below; or Best supportive Care (BSC) alone: * High intensity (intermediate or high dose cytarabine \[HiDAC\]; mitoxantrone, etoposide, and cytarabine \[MEC\]; or fludarabine, cytarabine, granulocyte colony stimulating factor \[G-CSF\], +/- idarubicin \[FLAG/FLAG-Ida\]). * Low intensity (low dose cytarabine \[LDAC\], decitabine, or azacitidine). * BSC.

Key facts

Study ID: NCT02920008
Run by: Astex Pharmaceuticals, Inc.
People needed: 302
Starts: 2017-03-16
Expected to finish: 2020-06-01
Last updated by the study team: 2024-08-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Adult participants ≥18 years of age who are able to understand study procedures, comply with them, and provide written informed consent before any study-specific procedure.
History of cytologically or histologically confirmed diagnosis of AML (except acute promyelocytic leukemia) according to the 2008 World Health Organization (WHO) classification (bone marrow [BM] or peripheral blood [PB] blast counts ≥20%).
Performance status (Eastern Cooperative Oncology Group; ECOG) of 0-2.
Participants with AML previously treated with initial induction therapy using a standard intensive chemotherapy regimen, including cytarabine and an anthracycline, and who are refractory to initial induction (primary refractory) or in relapse after such initial induction with or without prior HCT.
Participants must have either PB or BM blasts ≥5% at time of randomization.
Creatinine clearance or glomerular filtration rate ≥30 mL/min as estimated by the Cockroft-Gault (C-G) or other medically acceptable formulas, such as MDRD (Modification of Diet in Renal Disease) or CKD-EPI (the Chronic Kidney Disease Epidemiology Collaboration).
Women of child-bearing potential must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of child-bearing potential and men with female partners of child-bearing potential must agree to practice 2 highly effective contraceptive measures of birth control and must agree not to become pregnant or father a child (a) while receiving treatment of guadecitabine, decitabine, or azacitidine and for at least 3 months after completing treatment and (b) while receiving treatment with high-intensity TC or LDAC and for at least 6 months after completing treatment.

You may not qualify if…

Known clinically active central nervous system (CNS) or extramedullary AML, except leukemia cutis.
Participants who are in first relapse after initial induction, if they had a response duration of >12 months from date when first response first documented or if they are good candidates for HCT.
BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
Second malignancy currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy.
Grade 3 or higher Graft Versus Host Disease (GVHD), or GVHD on either a calcineurin inhibitor or prednisone more than 5 mg/day.
Prior treatment with guadecitabine for any indication, or more than 2 cycles of prior decitabine or azacitidine.
Hypersensitivity to decitabine, guadecitabine, or any of their excipients.
Treated with any investigational therapy within 2 weeks of the first dose of study treatment.
Total serum bilirubin >2.5 × upper limit of normal (ULN; except for participants with Gilbert's Syndrome for whom direct bilirubin is <2.5 × ULN), or liver cirrhosis, or chronic liver disease Child-Pugh Class B or C.
Known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer on antivirals is allowed.
Known significant mental illness or other condition such as active alcohol or other substance abuse or addiction that, in the opinion of the investigator, predisposes the participant to high risk of noncompliance with the protocol.
Refractory congestive heart failure unresponsive to medical treatment; active infection resistant to all antibiotics; or non-AML-associated pulmonary disease requiring >2 liters per minute (LPM) oxygen, or any other condition that puts the participant at an imminent risk of death.
Participants with high PB blasts >50% AND poor ECOG PS of 2.

Where it is running

The University of Chicago Medical Center — Chicago, Illinois, United States
Franciscan Research Center — Indianapolis, Indiana, United States
John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States
University of New Mexico School of Medicine — Albuquerque, New Mexico, United States
Roswell Park Cancer Institute — Buffalo, New York, United States
Weill Cornell Medical College — New York, New York, United States
Duke Cancer Institute — Durham, North Carolina, United States
University of Oklahoma Medical Center — Oklahoma City, Oklahoma, United States
Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
Temple University Hospital — Philadelphia, Pennsylvania, United States
Vanderbilt University Medical Center — Nashville, Tennessee, United States
Baylor Research Institute — Dallas, Texas, United States
MD Anderson Cancer Center — Houston, Texas, United States
West Virginia University Hospitals, Inc. — Morgantown, West Virginia, United States
AZ Sint-Jan Brugge-Oostende AV — Bruges, Belgium
Cliniques Universitaires Saint-Luc — Brussels, Belgium
Universitair Ziekenhuis Gent — Ghent, Belgium
Tom Baker Cancer Centre — Calgary, Alberta, Canada
University of Alberta Hospital — Edmonton, Alberta, Canada
Princess Margaret Cancer Centre — Toronto, Ontario, Canada
McGill University Health Centre — Montreal, Quebec, Canada
Hopital Maisonneuve Rosemont — Montreal, Canada
Aarhus University Hospital — Aarhus C, Denmark
Rigshospitalet — Copenhagen, Denmark
University of Southern California — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.